SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Quark Pharmaceuticals Inc. Granted European Orphan Drug Status for QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients